2023 Q1 Form 10-K Financial Statement
#000106299323008012 Filed on March 29, 2023
Income Statement
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|---|---|---|
| Revenue | $162.0K | $173.0K | $950.0K |
| YoY Change | -31.65% | -64.98% | -38.11% |
| Cost Of Revenue | $472.0K | $477.0K | $1.858M |
| YoY Change | 0.43% | -27.51% | -17.79% |
| Gross Profit | -$310.0K | -$304.0K | -$908.0K |
| YoY Change | 33.05% | 85.37% | 26.11% |
| Gross Profit Margin | -191.36% | -175.72% | -95.58% |
| Selling, General & Admin | $1.295M | $1.292M | $4.697M |
| YoY Change | 19.46% | -3.15% | 25.25% |
| % of Gross Profit | |||
| Research & Development | $822.0K | $742.0K | $3.031M |
| YoY Change | 3.01% | -8.05% | 11.43% |
| % of Gross Profit | |||
| Depreciation & Amortization | $192.0K | $190.0K | $777.0K |
| YoY Change | -1.54% | -5.94% | -1.77% |
| % of Gross Profit | |||
| Operating Expenses | $2.781M | $2.224M | $10.36M |
| YoY Change | 33.9% | -5.08% | 42.74% |
| Operating Profit | -$2.619M | -$2.528M | -$9.413M |
| YoY Change | 13.38% | 0.84% | 17.96% |
| Interest Expense | $319.0K | -$216.0K | $1.281M |
| YoY Change | -184.84% | -38.98% | -195.6% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$305.0K | -$1.277M | |
| YoY Change | -18.88% | -4.42% | |
| Pretax Income | -$2.924M | -$2.744M | -$10.69M |
| YoY Change | 8.86% | -4.09% | 14.72% |
| Income Tax | $0.00 | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$2.924M | -$2.744M | -$10.69M |
| YoY Change | 8.86% | -3.99% | 14.8% |
| Net Earnings / Revenue | -1804.94% | -1586.13% | -1125.26% |
| Basic Earnings Per Share | -$0.02 | -$0.07 | |
| Diluted Earnings Per Share | -$0.02 | -$0.02 | -$0.07 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 174.6M shares | 174.6M shares | 164.7M shares |
| Diluted Shares Outstanding | 174.6M shares | 164.7M shares |
Balance Sheet
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $3.840M | $2.527M | $2.527M |
| YoY Change | -62.53% | -74.6% | -74.6% |
| Cash & Equivalents | $2.520M | $1.210M | |
| Short-Term Investments | $1.320M | $1.317M | $1.317M |
| Other Short-Term Assets | $406.0K | $331.0K | $331.0K |
| YoY Change | 19.41% | 6.77% | 3.44% |
| Inventory | $70.00K | $62.00K | $62.00K |
| Prepaid Expenses | $212.0K | $137.0K | |
| Receivables | $590.0K | $709.0K | $709.0K |
| Other Receivables | $196.0K | $159.0K | $159.0K |
| Total Short-Term Assets | $5.102M | $3.788M | $3.788M |
| YoY Change | -56.23% | -66.88% | -66.89% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $4.318M | $4.425M | $5.157M |
| YoY Change | -29.49% | -15.12% | -17.09% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $245.0K | $245.0K | $245.0K |
| YoY Change | -4.3% | -2.78% | -2.0% |
| Total Long-Term Assets | $5.239M | $5.402M | $5.402M |
| YoY Change | -17.88% | -16.48% | -16.51% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $5.102M | $3.788M | $3.788M |
| Total Long-Term Assets | $5.239M | $5.402M | $5.402M |
| Total Assets | $10.34M | $9.190M | $9.190M |
| YoY Change | -42.66% | -48.67% | -48.69% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.514M | $2.102M | $2.102M |
| YoY Change | 6.93% | -8.57% | -8.61% |
| Accrued Expenses | $238.0K | $236.0K | $236.0K |
| YoY Change | -5.56% | -5.22% | -5.6% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Long-Term Debt Due | $8.500M | $0.00 | $36.00K |
| YoY Change | 22872.97% | -99.16% | |
| Total Short-Term Liabilities | $11.29M | $2.374M | $2.374M |
| YoY Change | 58.89% | -66.18% | -66.18% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $5.500M | $9.814M |
| YoY Change | -100.0% | 120.0% | 56.03% |
| Other Long-Term Liabilities | $375.0K | $425.0K | $425.0K |
| YoY Change | -37.91% | -33.8% | -33.59% |
| Total Long-Term Liabilities | $0.00 | $5.500M | $10.24M |
| YoY Change | -100.0% | 120.0% | 47.75% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $11.29M | $2.374M | $2.374M |
| Total Long-Term Liabilities | $0.00 | $5.500M | $10.24M |
| Total Liabilities | $16.65M | $12.61M | $12.61M |
| YoY Change | -4.41% | -10.13% | -10.1% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$71.45M | -$68.53M | |
| YoY Change | 18.43% | ||
| Common Stock | $1.000K | $1.000K | |
| YoY Change | 0.0% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$6.313M | -$3.423M | -$3.423M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $10.34M | $9.190M | $9.190M |
| YoY Change | -42.66% | -48.67% | -48.69% |
Cashflow Statement
| Concept | 2023 Q1 | 2022 Q4 | 2022 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$2.924M | -$2.744M | -$10.69M |
| YoY Change | 8.86% | -3.99% | 14.8% |
| Depreciation, Depletion And Amortization | $192.0K | $190.0K | $777.0K |
| YoY Change | -1.54% | -5.94% | -1.77% |
| Cash From Operating Activities | -$2.262M | -$2.553M | -$9.516M |
| YoY Change | -1.09% | 22.74% | 32.72% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $74.00K | $24.00K | $271.0K |
| YoY Change | -215.63% | -185.71% | -346.36% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $2.300M | $3.780M |
| YoY Change | -100.0% | -176.06% | |
| Cash From Investing Activities | -$74.00K | $2.276M | $3.509M |
| YoY Change | -103.79% | -8228.57% | -169.21% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $0.00 | ||
| YoY Change | -100.0% | ||
| Debt Paid & Issued, Net | $0.00 | ||
| YoY Change | -100.0% | ||
| Cash From Financing Activities | $3.648M | -10.00K | $2.965M |
| YoY Change | 21.97% | 25.0% | -80.86% |
| NET CHANGE | |||
| Cash From Operating Activities | -$2.262M | -2.553M | -$9.516M |
| Cash From Investing Activities | -$74.00K | 2.276M | $3.509M |
| Cash From Financing Activities | $3.648M | -10.00K | $2.965M |
| Net Change In Cash | $1.312M | -287.0K | -$3.042M |
| YoY Change | -50.66% | -86.44% | -193.6% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$2.262M | -$2.553M | -$9.516M |
| Capital Expenditures | $74.00K | $24.00K | $271.0K |
| Free Cash Flow | -$2.336M | -$2.577M | -$9.787M |
| YoY Change | 5.08% | 25.58% | 38.63% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2022 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-12-31 | |
| CY2022 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2022 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
| CY2022 | dei |
Entity Registrant Name
EntityRegistrantName
|
IntelGenx Technologies Corp. | |
| CY2023Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
174646197 | shares |
| CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
|
48000 | usd |
| CY2021 | igxt |
Stock Issued During Period Value New Issues Two
StockIssuedDuringPeriodValueNewIssuesTwo
|
8398000 | usd |
| CY2021 | igxt |
Stock Issued During Period Value Conversion Of Convertible Notes
StockIssuedDuringPeriodValueConversionOfConvertibleNotes
|
632000 | usd |
| CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
|
325000 | usd |
| CY2022 | igxt |
Stock Issued During Period Interest Paid Value
StockIssuedDuringPeriodInterestPaidValue
|
171000 | usd |
| CY2022 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
0 | usd |
| CY2021 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-6000 | usd |
| CY2022 | us-gaap |
Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
|
0 | usd |
| CY2022 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | usd |
| CY2021 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
12346000 | usd |
| CY2022 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
0 | usd |
| CY2021 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
422000 | usd |
| CY2021 | igxt |
Proceeds From Issuance Convertible Notes
ProceedsFromIssuanceConvertibleNotes
|
1897000 | usd |
| CY2021 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
737000 | usd |
| CY2017Q3 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
1 | |
| CY2020Q2 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
0.5 | |
| CY2017Q3 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
5049000 | usd |
| CY2017Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
7600000 | cad |
| CY2017Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
5611000 | usd |
| CY2017Q3 | igxt |
Proceeds From Convertible Debt Amount Per Instrument
ProceedsFromConvertibleDebtAmountPerInstrument
|
1000 | cad |
| CY2017Q3 | igxt |
Proceeds From Convertible Debt Amount Per Instrument
ProceedsFromConvertibleDebtAmountPerInstrument
|
738 | usd |
| CY2017Q3 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
1.35 | |
| CY2017Q3 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
6838000 | cad |
| CY2017Q3 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
5049000 | usd |
| CY2017Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
6838000 | cad |
| CY2022 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
60000 | cad |
| CY2022 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
48000 | usd |
| CY2022 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
218000 | cad |
| CY2022 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
171000 | usd |
| CY2018Q2 | igxt |
Subscription Price Of Units
SubscriptionPriceOfUnits
|
10000 | usd |
| CY2018Q2 | us-gaap |
Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
|
3200000 | usd |
| CY2018Q2 | igxt |
Warrants Issued During Period Warrants
WarrantsIssuedDuringPeriodWarrants
|
7690 | shares |
| CY2018Q2 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
0.8 | |
| CY2018Q2 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
0.8 | |
| CY2018Q2 | igxt |
Commission Paid To Agents
CommissionPaidToAgents
|
157800 | usd |
| CY2018Q2 | us-gaap |
Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
|
243275 | shares |
| CY2018Q2 | igxt |
Equity Issuance Amount Per Share
EquityIssuanceAmountPerShare
|
0.8 | |
| CY2018Q2 | igxt |
Warrants Issued During Period Value
WarrantsIssuedDuringPeriodValue
|
50000 | usd |
| CY2022 | igxt |
Gross Proceeds Of Units
GrossProceedsOfUnits
|
3200000 | usd |
| CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
100000 | shares |
| CY2021Q4 | igxt |
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
|
0.2 | |
| CY2021Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
41156990 | shares |
| CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
44000 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
425000 | usd |
| CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2022Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
0 | usd |
| CY2021Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
79000 | usd |
| CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
| CY2022 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2022 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2022Q4 | igxt |
Subsequent Event
SubsequentEvent
|
usd | |
| CY2021Q4 | igxt |
Subsequent Event
SubsequentEvent
|
usd | |
| CY2021 | igxt |
Transaction Cost For Common Stock Issued
TransactionCostForCommonStockIssued
|
297000 | usd |
| CY2021Q4 | us-gaap |
Deferred Tax Liabilities Deferred Expense Deferred Financing Costs
DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
|
86000 | usd |
| CY2022 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1277000 | usd |
| CY2021 | us-gaap |
Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
|
-354000 | usd |
| CY2022 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
0 | usd |
| CY2017Q3 | igxt |
Debt Instrument Convertible Number Of Shares Per Instrument
DebtInstrumentConvertibleNumberOfSharesPerInstrument
|
740 | shares |
| CY2022 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <div> <div> <div> <p style="margin-left:18pt;text-indent:-18pt;text-align:justify;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>3. </strong><strong>Nature of Business</strong></span></span></p> <p style="margin-left:18pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IntelGenx was incorporated in the State of Delaware as Big Flash Corp. on July 27, 1999. On April 28, 2006 Big Flash Corp. completed, through the Canadian holding corporation, the acquisition of IntelGenx Corp., a company incorporated in Canada on June 15, 2003 and headquartered in Montreal, Quebec. IntelGenx Corp. has continued operations as our operating subsidiary.</span></span></p> <p style="margin-left:18pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">IntelGenx Corp. is a drug delivery company focused on the contract development and manufacturing of novel oral thin film products for the pharmaceutical market. More recently, IntelGenx made the strategic decision to enter the Canadian cannabis market with a non-prescription cannabis infused oral film that launched in early 2021 and in 2020 made the decision to enter the psychedelic market. As a full service contract development and manufacturing organization ("CDMO") IntelGenx is offering partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical research and development, clinical monitoring, regulatory support, technology transfer, manufacturing scale-up, and commercial manufacturing. The Company's main product development efforts are based upon three delivery platform technologies: (1) VersaFilm™, an oral film technology, (2) the VetaFilm<sup>TM</sup> technology platform for veterinary applications and (3) DisinteQ™ a disintegrating oral film technology.</span></span></p> <p style="margin-left:18pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's business strategy is to leverage its proprietary drug delivery technologies and develop pharmaceutical products with tangible benefits for patients, for partners and, once the product launches, retain the exclusive manufacturing rights. </span></span></p> <p style="margin-left:18pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Managing the project pipeline is a key Company success factor. Three focus areas have been identified; psychedelics, cannabis and animal health where the Company believes it can establish a leadership position with its drug delivery technology. The Company has undertaken a strategy under which it will work with pharmaceutical companies in order to apply its oral film technology to pharmaceutical products for which patent protection is nearing expiration, a strategy which is often referred to as "lifecycle management." Under §505(b)(2) of the Food, Drug, and Cosmetics Act (the "FDCA"), the FDA may grant market exclusivity for a term of up to three years following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage, dosage form, route of administration or a combination.</span></span></p> <p style="margin-left:18pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company's product portfolio includes a blend of generic and branded products based on its proprietary delivery technology ("generic" products are essentially copies of products that have already received FDA approval). Of the 12 projects currently in the Company's portfolio, 11 use the <i>VersaFilm™</i> technology and one uses the <i>VetaFilm™</i> technology.</span></span></p> </div> </div> </div> </div> | |
| CY2017Q3 | igxt |
Proceeds From Convertible Debt Amount Per Instrument
ProceedsFromConvertibleDebtAmountPerInstrument
|
738 | usd |
| CY2017Q3 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
762000 | cad |
| CY2017Q3 | igxt |
Proceeds From Convertible Debt Amount Per Instrument
ProceedsFromConvertibleDebtAmountPerInstrument
|
1000 | cad |
| CY2021Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | usd |
| CY2022Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
5500000 | usd |
| CY2021Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
2500000 | usd |
| CY2017Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
5049000 | usd |
| CY2017Q3 | igxt |
Proceeds From Convertible Debt Amount Per Instrument
ProceedsFromConvertibleDebtAmountPerInstrument
|
1000 | cad |
| CY2017Q3 | igxt |
Proceeds From Convertible Debt Amount Per Instrument
ProceedsFromConvertibleDebtAmountPerInstrument
|
738 | usd |
| CY2017Q3 | us-gaap |
Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
|
0.08 | pure |
| CY2017Q3 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
1.35 | |
| CY2017Q3 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
1 | |
| CY2022Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
5500000 | usd |
| CY2021Q4 | us-gaap |
Secured Long Term Debt
SecuredLongTermDebt
|
2500000 | usd |
| CY2022Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
5500000 | usd |
| CY2021Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
2500000 | usd |
| CY2022Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
0 | usd |
| CY2017Q3 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
563000 | usd |
| CY2017Q3 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
6838000 | cad |
| CY2020Q2 | us-gaap |
Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
|
0.37 | |
| CY2022 | igxt |
Stock Issued During Period Shares Repayment Of Convertible Debentures In Shares
StockIssuedDuringPeriodSharesRepaymentOfConvertibleDebenturesInShares
|
19381223 | shares |
| CY2022Q2 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
5450000 | cad |
| CY2022Q2 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
4229000 | usd |
| CY2022Q4 | igxt |
Face Value Of Convertible Debentures
FaceValueOfConvertibleDebentures
|
3866000 | usd |
| CY2021Q4 | igxt |
Face Value Of Convertible Debentures
FaceValueOfConvertibleDebentures
|
3977000 | usd |
| CY2022 | us-gaap |
Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
|
73000 | usd |
| CY2021 | us-gaap |
Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
|
74000 | usd |
| CY2022 | igxt |
Accretion
Accretion
|
436000 | usd |
| CY2021 | igxt |
Accretion
Accretion
|
344000 | usd |
| CY2022 | igxt |
Stock Issued During Period Repayment For Convertible Of Debentures
StockIssuedDuringPeriodRepaymentForConvertibleOfDebentures
|
4229000 | usd |
| CY2021 | igxt |
Stock Issued During Period Repayment For Convertible Of Debentures
StockIssuedDuringPeriodRepaymentForConvertibleOfDebentures
|
0 | usd |
| CY2022Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
0 | usd |
| CY2021Q4 | us-gaap |
Convertible Debt
ConvertibleDebt
|
4247000 | usd |
| CY2022 | igxt |
Accretion Expense On Convertible Debt
AccretionExpenseOnConvertibleDebt
|
125000 | cad |
| CY2022 | igxt |
Accretion Expense On Convertible Debt
AccretionExpenseOnConvertibleDebt
|
96000 | usd |
| CY2021 | igxt |
Accretion Expense On Convertible Debt
AccretionExpenseOnConvertibleDebt
|
288000 | cad |
| CY2021 | igxt |
Accretion Expense On Convertible Debt
AccretionExpenseOnConvertibleDebt
|
230000 | usd |
| CY2021 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
1926000 | cad |
| CY2021 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
1519000 | usd |
| CY2021 | igxt |
Interest Paid By Issuance Of Common Shares Shares
InterestPaidByIssuanceOfCommonSharesShares
|
573684 | shares |
| CY2021 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
549000 | cad |
| CY2021 | us-gaap |
Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
|
438000 | usd |
| CY2018Q2 | us-gaap |
Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
|
320 | shares |
| CY2018Q2 | igxt |
Interest Rate On Convertible Note
InterestRateOnConvertibleNote
|
0.06 | pure |
| CY2022 | igxt |
Transaction Costs Of Units
TransactionCostsOfUnits
|
328000 | usd |
| CY2022 | igxt |
Net Proceeds Of Units
NetProceedsOfUnits
|
2872000 | usd |
| CY2022Q4 | us-gaap |
Purchase Obligation
PurchaseObligation
|
1911000 | eur |
| CY2022Q4 | us-gaap |
Purchase Obligation
PurchaseObligation
|
2040000 | usd |
| CY2022Q4 | igxt |
Payments Made In Respect To Purchase Obligation
PaymentsMadeInRespectToPurchaseObligation
|
1490000 | eur |
| CY2022Q4 | igxt |
Payments Made In Respect To Purchase Obligation
PaymentsMadeInRespectToPurchaseObligation
|
1591000 | usd |
| CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | shares |
| CY2022Q4 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
6000 | usd |
